Effect of rituximab on the manifestations of activity and pulmonary function in patients with systemic sclerosis: one-year follow-up evaluation

Effect of rituximab on the manifestations of activity and pulmonary function in patients with systemic sclerosis: one-year follow-up evaluation

The choice of drugs for the treatment of interstitial lung disease (ILD) associated with systemic sclerosis (SS) is currently very limited. Data from a number of studies show that rituximab (RTM) can improve lung function and reduce the severity of skin fibrosis in patients with SS.Objective: to eva...

Full description

Saved in:
Bibliographic Details
Main Authors: L. P. Ananyeva, O. A. Koneva, O. V. Desinova, L. A. Garzanova, S. I. Glukhova, M. N. Starovoitova, O. B. Ovsyannikova, A. V. Volkov, A. P. Aleksankin, E. L. Nasonov
Format: Article
Language:Russian
Published: IMA PRESS LLC 2019-07-01
Series:Научно-практическая ревматология
Subjects:
systemic sclerosis
interstitial lung disease
anti-b cell therapy
rituximab
Online Access:https://rsp.mediar-press.net/rsp/article/view/2724
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://rsp.mediar-press.net/rsp/article/view/2724

Similar Items